Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| PEG-MGF (Pegylated Mechano Growth Factor) | Thymosin Alpha-1 | |
|---|---|---|
| Category | Growth Factors | Growth Factors |
| Standard Dose | Research indicates 200-500 mcg administered 2-3 times per week via subcutaneous or intramuscular injection. | Research indicates 1.6 mg administered twice weekly via subcutaneous injection. |
| Timing | On non-training days or several hours post-workout (to avoid competing with natural MGF pulse). Unlike native MGF, timing is more flexible due to extended half-life. | Morning administration preferred. No food timing restrictions. |
| Cycle Duration | 4-8 week cycles. | 8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance. |
| Evidence Level | animal_plus_anecdotal | strong_human |
PEG-MGF is the pegylated form of Mechano Growth Factor, where polyethylene glycol (PEG) molecules are covalently attached to protect against rapid enzymatic breakdown. This extends the half-life from 5-7 minutes (native MGF) to approximately 48-72 hours. Like native MGF, it activates satellite cell proliferation, promotes muscle fiber regeneration and hypertrophy, and supports tissue repair. The extended half-life allows for systemic distribution rather than purely local action, enabling subcutaneous rather than intramuscular administration.
Research indicates 200-500 mcg administered 2-3 times per week via subcutaneous or intramuscular injection.
On non-training days or several hours post-workout (to avoid competing with natural MGF pulse). Unlike native MGF, timing is more flexible due to extended half-life.
4-8 week cycles.
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus that acts as a pleiotropic immune modulator through Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on myeloid and plasmacytoid dendritic cells. It activates downstream IRF3, NF-kB, p38MAPK, and MyD88 signaling pathways to promote cytokine production. It modulates TNF-alpha, IFN-gamma, and IL-2 in CD4+ and CD8+ T lymphocytes by upregulating CD40/CD40L and downregulating PD-L1/PD-1 expression, enhancing both innate and adaptive immunity.
Research indicates 1.6 mg administered twice weekly via subcutaneous injection.
Morning administration preferred. No food timing restrictions.
8-12 week cycles, with periodic breaks. Some protocols use continuous low-dose maintenance.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →